[FG] Wild Damian

Gaonkar, Raghuvir H. et al. (2025) ‘Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4’, ChemMedChem [Preprint]. Available at: https://doi.org/10.1002/cmdc.202400773.

Basaco Bernabeu, Tais et al. (2024) ‘Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study’, Frontiers in Nuclear Medicine, 4. Available at: https://doi.org/10.3389/fnume.2024.1481343.

Santini, Francesco et al. (2024) ‘ESR Essentials: advanced MR safety in vulnerable patients—practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology’, European Radiology [Preprint]. Available at: https://doi.org/10.1007/s00330-024-11055-1.

Basaco Bernabeu, Tais et al. (2024) ‘61 Cu-PSMA–Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging’, Journal of Nuclear Medicine, 65(9), pp. 1427–1434. Available at: https://doi.org/10.2967/jnumed.123.267126.

Barzaghi, Leonardo et al. (2024) ‘Muscle diffusion tensor imaging in facioscapulohumeral muscular dystrophy’, Muscle & Nerve, 70(2), pp. 248–256. Available at: https://doi.org/10.1002/mus.28179.

Eigler, Christopher et al. (2024) ‘Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study’, Journal of Nuclear Medicine, 65(4), pp. 573–579. Available at: https://doi.org/10.2967/jnumed.123.266817.

Barzaghi, Leonardo et al. (2024) ‘Myo-regressor Deep Informed Neural NetwOrk (Myo-DINO) for fast MR parameters mapping in neuromuscular disorders’, Computer Methods and Programs in Biomedicine [Preprint]. Available at: https://doi.org/https://doi.org/10.1016/j.cmpb.2024.108399.

Beck, Julia et al. (2024) ‘Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms’, Endocrine-Related Cancer, 31. Available at: https://doi.org/10.1530/erc-23-0235.

Boss, Marti et al. (2024) ‘Improved Localization of Insulinomas Using 68 Ga-NODAGA-Exendin-4 PET/CT’, Journal of Nuclear Medicine, 65, pp. 1959–1964. Available at: https://doi.org/10.2967/jnumed.124.268158.

Busslinger, Sarah D. et al. (2024) ‘Comparison of the tolerability of 161 Tb- and 177 Lu-labeled somatostatin analogues in the preclinical setting’, European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 4049–4061. Available at: https://doi.org/10.1007/s00259-024-06827-2.

Chirindel, Alin et al. (2024) ‘First-in-human administration of [ 161 Tb]Tb-SibuDAB and comparative dosimetry with standard [ 177 Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study’, European Journal of Nuclear Medicine and Molecular Imaging [Preprint]. Available at: https://doi.org/10.1007/s00259-024-07009-w.

Erdil, Ertunc et al. (2024) ‘Correction to: Predicting standardized uptake value of brown adipose tissue from CT scans using convolutional neural networks (Nature Communications, (2024), 15, 1, (8402), 10.1038/s41467-024-52622-w)’, Nature Communications, 15. Available at: https://doi.org/10.1038/s41467-024-54209-x.

Erdil, Ertunc et al. (2024) ‘Predicting standardized uptake value of brown adipose tissue from CT scans using convolutional neural networks’, Nature Communications, 15. Available at: https://doi.org/10.1038/s41467-024-52622-w.

Fricke, Julia et al. (2024) ‘First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([ 161 Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum’, European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 2517–2519. Available at: https://doi.org/10.1007/s00259-024-06641-w.

Rottenburger, Christof et al. (2024) ‘Results of the phase I “Lumed ” study: Dose escalation of 177Lu-PP-F11N in patients with medullary thyroid carcinoma.’, in Annual Congress of the European Association of Nuclear Medicine . Hamburg, Deutschland (Annual Congress of the European Association of Nuclear Medicine ).

Schürrle, Seval Beykan et al. (2024) ‘Dosimetry and pharmacokinetics of [ 177 Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours’, European Journal of Nuclear Medicine and Molecular Imaging [Preprint]. Available at: https://doi.org/10.1007/s00259-024-06682-1.

von Niederhäusern, P.A. et al. (2024) ‘Augmented reality for sentinel lymph node biopsy’, International Journal of Computer Assisted Radiology and Surgery, 19(1), pp. 171–180. Available at: https://doi.org/10.1007/s11548-023-03014-w.

Wang, Tongtong et al. (2024) ‘Single-nucleus transcriptomics identifies separate classes of UCP1 and futile cycle adipocytes’, Cell Metabolism, 36, pp. 2130–2145.e7. Available at: https://doi.org/10.1016/j.cmet.2024.07.005.

Hemmig, Andrea K. et al. (2023) ‘Magnetic Resonance Imaging Findings Corresponding to Vasculitis as Defined via [18F]FDG Positron Emission Tomography or Ultrasound’, Diagnostics, 13(23). Available at: https://doi.org/10.3390/diagnostics13233559.

Kudura, Ken et al. (2023) ‘An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data’, Cancers, 15(22), p. 5476. Available at: https://doi.org/10.3390/cancers15225476.

von Niederhäusern, Peter A. et al. (2023) ‘Augmented reality for sentinel lymph node biopsy’, International Journal of Computer Assisted Radiology and Surgery, 19(1), pp. 171–180. Available at: https://doi.org/10.1007/s11548-023-03014-w.

Kudura, Ken et al. (2023) ‘Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition’, Journal of Clinical Medicine, 12(11), p. 3725. Available at: https://doi.org/10.3390/jcm12113725.

Askari E et al. (2023) ‘Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review’, Journal of Nuclear Medicine Technology, 51(1), pp. 22–25. Available at: https://doi.org/10.2967/jnmt.122.264904.

Kudura K et al. (2023) ‘Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival’, Cancers, 15(5). Available at: https://doi.org/10.3390/cancers15051521.

Fani, Melpomeni and Nicolas, Guillaume P. (2023) ‘61Cu-labeled radiotracers: Alternative or choice?’, Journal of Nuclear Medicine, 64(12), pp. 1855–1857. Available at: https://doi.org/10.2967/jnumed.123.266171.

Imperiale, Alessio et al. (2023) ‘The Emergence of Somatostatin Antagonist–Based Theranostics: Paving the Road Toward Another Success?’, Journal of Nuclear Medicine, 64(5), pp. 682–684. Available at: https://doi.org/10.2967/jnumed.123.265406.

Karnam, Murali et al. (2023) ‘Qualitative and quantitative assessment of admittance controllers for hand-guiding surgical robots’, At-Automatisierungstechnik, 71, pp. 515–527. Available at: https://doi.org/10.1515/auto-2023-0063.

Mallaev, Makhmudbek et al. (2023) ‘3D-Quantitated Single Photon Emission Computed Tomography/Computed Tomography: Impact on intended Management Compared to Lung Perfusion Scan in Marginal Candidates for Pulmonary Resection’, Clinical Lung Cancer, 24(7), pp. 621–630. Available at: https://doi.org/10.1016/j.cllc.2023.07.006.

Maushart, Claudia Irene et al. (2023) ‘Effect of high-dose glucocorticoid treatment on human brown adipose tissue activity: a randomised, double-blinded, placebo-controlled cross-over trial in healthy men’, eBioMedicine, 96. Available at: https://doi.org/10.1016/j.ebiom.2023.104771.

Schmidlin, Moira et al. (2023) ‘Improvement of Lung NET Management through Standardized Care—A Swiss Nationwide Observational Study’, Cancers, 15. Available at: https://doi.org/10.3390/cancers15082270.

Sira, Lívia et al. (2023) ‘Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies’, Frontiers in Endocrinology, 14. Available at: https://doi.org/10.3389/fendo.2023.1095815.

Wild, Damian and Fani, Melpomeni (2023) ‘Case Study #6: [ 177 Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy’, in Radiopharmaceutical Therapy. Cham: Springer International Publishing (Radiopharmaceutical Therapy), pp. 335–348. Available at: https://doi.org/10.1007/978-3-031-39005-0_16.

Wild, Damian et al. (2023) ‘A phase I/II study of the safety and efficacy of [ 177 Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours’, European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 183–195. Available at: https://doi.org/10.1007/s00259-023-06383-1.

Antwi K et al. (2022) ‘Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an 18F-FDG PET/CT after COVID-19 Vaccination’, Diagnostics, 12(12). Available at: https://doi.org/10.3390/diagnostics12123073.

Kudura K et al. (2022) ‘Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors’, Cancers, 14(24). Available at: https://doi.org/10.3390/cancers14246095.

Varum F et al. (2022) ‘Targeted colonic release formulations of mesalazine – A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis’, International Journal of Pharmaceutics, 625, p. 122055. Available at: https://doi.org/10.1016/j.ijpharm.2022.122055.

Hasegawa S. et al. (2022) ‘Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors’, Cancers, 14(14). Available at: https://doi.org/10.3390/cancers14143317.

Refardt J et al. (2022) ‘Molecular Imaging of Neuroendocrine Neoplasms’, Journal of Clinical Endocrinology and Metabolism, 107(7), pp. E2662–E2670. Available at: https://doi.org/10.1210/clinem/dgac207.

Christ E, Wild D and Refardt J (2022) ‘Molecular Imaging in neuroendocrine neoplasias’, Presse Medicale, 51(2), p. 104115. Available at: https://doi.org/10.1016/j.lpm.2022.104115.

Freitag MT et al. (2022) ‘Quantitative myocardial perfusion 82Rb-PET assessed by hybrid PET/coronary-CT: Normal values and diagnostic performance’, Journal of Nuclear Cardiology, 29(2), pp. 464–473. Available at: https://doi.org/10.1007/s12350-020-02264-4.

Hicks RJ et al. (2022) ‘ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours’, Journal of Neuroendocrinology, 34(3), p. e13040. Available at: https://doi.org/10.1111/jne.13040.

Imfeld S et al. (2022) ‘A Simplified PET/CT Measurement Routine with Excellent Diagnostic Accuracy for the Diagnosis of Giant Cell Arteritis’, Diagnostics, 12(3). Available at: https://doi.org/10.3390/diagnostics12030728.

Prasad V et al. (2022) ‘Reply: 68Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication’, Journal of Nuclear Medicine, 63(3), pp. 493–494. Available at: https://doi.org/10.2967/JNUMED.121.263167.

Boss M et al. (2022) ‘68Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism’, Journal of Nuclear Medicine, 63(2), pp. 310–315. Available at: https://doi.org/10.2967/JNUMED.121.262327.

Hayes AR et al. (2021) ‘Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy’, Journal of Clinical Endocrinology and Metabolism, 106(12), pp. E4903–E4916. Available at: https://doi.org/10.1210/clinem/dgab588.

Refardt J et al. (2021) ‘New Directions in Imaging Neuroendocrine Neoplasms’, Current Oncology Reports, 23(12), p. 143. Available at: https://doi.org/10.1007/s11912-021-01139-2.

Theiler D. et al. (2021) ‘Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients’, Cancers, 13(24). Available at: https://doi.org/10.3390/cancers13246290.

von Guggenberg E et al. (2021) ‘Update on preclinical development and clinical translation of cholecystokinin-2 receptor targeting radiopharmaceuticals’, Cancers, 13(22). Available at: https://doi.org/10.3390/cancers13225776.

Kobayashi N et al. (2021) ‘Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors’, Journal of Hepato-Biliary-Pancreatic Sciences, 28(9), pp. 727–739. Available at: https://doi.org/10.1002/jhbp.1014.

Refardt J et al. (2021) ‘Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges’, Reviews in Endocrine and Metabolic Disorders, 22(3), pp. 581–594. Available at: https://doi.org/10.1007/s11154-020-09552-x.

Wild D et al. (2021) ‘Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?’, Journal of Nuclear Medicine, 62(Suppl 2), pp. 44S–50S. Available at: https://doi.org/10.2967/jnumed.120.246009.

Rottenburger, Christof et al. (2021) ‘18F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches’, Swiss Medical Weekly, 151(23-24). Available at: https://doi.org/10.4414/smw.2021.20512.

Antwi K et al. (2021) ‘Research article investigating difficult to detect pancreatic lesions: Characterization of benign pancreatic islet cell tumors using multiparametric pancreatic 3-T MRI’, PLoS ONE, 16(6 June 2021), p. e0253078. Available at: https://doi.org/10.1371/journal.pone.0253078.

Mansi R and Fani M (2021) ‘Radiolabeled peptides for cancer imaging and therapy: From bench-to-bedside’, Chimia, 75(6), pp. 500–504. Available at: https://doi.org/10.2533/chimia.2021.500.

Gaonkar RH et al. (2021) ‘SPECT imaging of SST2-expressing tumors with 99mTc-based somatostatin receptor antagonists: The role of tetraamine, HYNIC, and spacers’, Pharmaceuticals, 14(4). Available at: https://doi.org/10.3390/ph14040300.

Ambrosini V et al. (2021) ‘Consensus on molecular imaging and theranostics in neuroendocrine neoplasms’, European Journal of Cancer, 146, pp. 56–73. Available at: https://doi.org/10.1016/j.ejca.2021.01.008.

Braun M et al. (2021) ‘Accuracy comparison of various quantitative [99mTc]Tc-DPD SPECT/CT reconstruction techniques in patients with symptomatic hip and knee joint prostheses’, EJNMMI Research, 11(1), p. 60. Available at: https://doi.org/10.1186/s13550-021-00794-7.

Fani M et al. (2021) ‘Selection of the first99mtc-labelled somatostatin receptor subtype 2 antagonist for clinical translation—preclinical assessment of two optimized candidates’, Pharmaceuticals, 14(1), pp. 1–15. Available at: https://doi.org/10.3390/ph14010019.

Hess, Gabriel Fridolin et al. (2021) ‘Surgical Strategy Based on Radiological 3D Reconstruction in a Giant Metastatic Neuroendocrine Tumor of the Pancreas: A Case Report of an Interdisciplinary Approach’, Case Reports in Surgery, 2021(8811155). Available at: https://doi.org/10.1155/2021/8811155.

Preisig, Daniel et al. (2021) ‘Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: a clinical pharmacoscintigraphy study’, European Journal of Pharmaceutics and Biopharmaceutics, 165, pp. 22–30. Available at: https://doi.org/10.1016/j.ejpb.2021.05.002.

Schaerli N et al. (2020) ‘Incremental value of high-frequency QRS analysis for diagnosis and prognosis in suspected exercise-induced myocardial ischaemia’, European Heart Journal: Acute Cardiovascular Care, 9(8), pp. 836–847. Available at: https://doi.org/10.1177/2048872619842988.

Häfliger S et al. (2020) ‘Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor’. S. Karger AG, 13(3). Available at: https://doi.org/10.1159/000510334.

Rottenburger C and Lutz T (2020) ‘[The ablative radioiodine therapy of differentiated thyroid carcinoma].’, Therapeutische Umschau. Revue therapeutique, 77(9), pp. 427–431. Available at: https://doi.org/10.1024/0040-5930/a001214.

Caobelli F et al. (2020) ‘Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores’, Journal of Nuclear Cardiology, 27(5), pp. 1456–1463. Available at: https://doi.org/10.1007/s12350-019-01893-8.

Antwi K et al. (2020) ‘Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging’, Clinical Nuclear Medicine, 45(9), pp. E386–E392. Available at: https://doi.org/10.1097/RLU.0000000000003124.

Mansi R et al. (2020) ‘Evaluation of a new 177lu-labeled somatostatin analog for the treatment of tumors expressing somatostatin receptor subtypes 2 and 5’, Molecules, 25(18). Available at: https://doi.org/10.3390/molecules25184155.

Schunemann M.J. et al. (2020) ‘Wither Away: Weight Loss and Persistent Inflammation in a Woman With Whipple Disease’, American Journal of Medicine, 133(6), pp. e223–e226. Available at: https://doi.org/10.1016/j.amjmed.2019.08.058.

Imfeld S et al. (2020) ‘FDG positron emission tomography and ultrasound in the diagnosis of giant cell arteritis: Congruent or complementary imaging methods?’, Rheumatology (United Kingdom), 59(4), pp. 772–778. Available at: https://doi.org/10.1093/rheumatology/kez362.

Rottenburger C et al. (2020) ‘Cholecystokinin 2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: Results of the lumed phase 0a study’, Journal of Nuclear Medicine, 61(4), pp. 520–523. Available at: https://doi.org/10.2967/jnumed.119.233031.

Maas O et al. (2020) ‘Variations in radioiodine ablation: decision-making after total thyroidectomy’, European Journal of Nuclear Medicine and Molecular Imaging, 47(3), pp. 554–560. Available at: https://doi.org/10.1007/s00259-019-04557-4.

Christ E et al. (2020) ‘Innovative imaging of insulinoma: The end of sampling? a review’, Endocrine-Related Cancer, 27(4), pp. R79–R92. Available at: https://doi.org/10.1530/ERC-19-0476.

Coto-Llerena, Mairene et al. (2020) ‘High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes’, Frontiers in Oncology, 10, p. 979. Available at: https://doi.org/10.3389/fonc.2020.00979.

Fischer JGW et al. (2020) ‘Comparison of [18F]FDG PET/CT with magnetic resonance imaging for the assessment of human brown adipose tissue activity’, EJNMMI Research, 10(1), p. 85. Available at: https://doi.org/10.1186/s13550-020-00665-7.

Hepprich M et al. (2020) ‘Brunner’s Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging’. Hindawi Limited410 Park Avenue, 15th Floor, 287 pmbNew YorkNY 10022, 2020. Available at: https://doi.org/10.1155/2020/4510910.

Mansi R et al. (2020) ‘A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting’, EJNMMI Research, 10(1), p. 90. Available at: https://doi.org/10.1186/s13550-020-00677-3.

von Niederhäusern PA et al. (2019) ‘Augmenting camera images with gamma detector data: A novel approach to support sentinel lymph node biopsy’, EJNMMI Physics, 6(1), p. 10. Available at: https://doi.org/10.1186/s40658-019-0245-z.

von Niederhäusern, Peter A. et al. (2019) ‘Augmenting camera images with gamma detector data’, EJNMMI Physics, 6(1). Available at: https://doi.org/10.1186/s40658-019-0245-z.

Zamboglou C et al. (2019) ‘Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.’, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 141, pp. 208–213. Available at: https://doi.org/10.1016/j.radonc.2019.07.002.

Antwi K et al. (2019) ‘Ga-Exendin-4 PET/CT Detects Insulinomas in Patients with Endogenous Hyperinsulinemic Hypoglycemia in MEN-1’, Journal of Clinical Endocrinology and Metabolism, 104(12), pp. 5843–5852. Available at: https://doi.org/10.1210/jc.2018-02754.

Mansi R. and Fani M. (2019) ‘Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors’, Journal of Labelled Compounds and Radiopharmaceuticals, 62(10), pp. 635–645. Available at: https://doi.org/10.1002/jlcr.3755.

Buitinga M et al. (2019) ‘Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients’, Journal of Nuclear Medicine. 30.11.2018, 60(6), pp. 812–816. Available at: https://doi.org/10.2967/jnumed.118.219980.

Wolf KI et al. (2019) ‘Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE’. Springer Verlagservice@springer.de, 53(3). Available at: https://doi.org/10.1007/s13139-019-00579-w.

Antwi K et al. (2019) ‘Volume Replacement Fluid Demarks Benign Insulinoma with 68Ga-DOTA-Exendin-4 PET/CT’, Clinical Nuclear Medicine, 44(5), pp. E347–E348. Available at: https://doi.org/10.1097/RLU.0000000000002522.

Aschwanden M et al. (2019) ‘Vessel wall plasticity in large vessel giant cell arteritis: An ultrasound follow-up study’, Rheumatology (United Kingdom), 58(5), pp. 792–797. Available at: https://doi.org/10.1093/rheumatology/key383.

Dastamani A et al. (2019) ‘The use of a long-acting somatostatin analogue (lanreotide) in three children with focal forms of congenital hyperinsulinaemic hypoglycaemia’. S. Karger AG, 91(1). Available at: https://doi.org/10.1159/000491101.

Antwi K et al. (2019) ‘Molecular imaging for neuroendocrine tumours’, Swiss Medical Weekly, 149(9-10), p. w20017. Available at: https://doi.org/10.4414/smw.2019.20017.

Beykan S et al. (2019) ‘In vivo biokinetics of 177Lu-OPS201 in mice and pigs as a model for predicting human dosimetry’, Contrast Media and Molecular Imaging, 2019, p. 6438196. Available at: https://doi.org/10.1155/2019/6438196.

Honegger, Ursina et al. (2019) ‘Prevalence and determinants of exercise-induced left ventricular dysfunction in patients with coronary artery disease’, European journal of clinical investigation, 49(6), p. e13112. Available at: https://doi.org/10.1111/eci.13112.

Sauter AW et al. (2019) ‘Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177 Lu-DOTA-PP-F11N: Does the use of protease inhibitors further improve in vivo distribution?’, Journal of Nuclear Medicine. 12.07.2018, 60(3), pp. 393–399. Available at: https://doi.org/10.2967/jnumed.118.207845.

von Niederhausern P.A. et al. (2019) ‘Gamma Source Location Learning from Synthetic Multi-pinhole Collimator Data’. Springer Science and Business Media Deutschland GmbH, pp. 205–214. Available at: https://doi.org/10.1007/978-3-030-33843-5_19.

von Niederhäusern, Peter et al. (2019) ‘Gamma Source Location Learning from Synthetic Multi-pinhole Collimator Data’, in Knoll, Florian;Maier, Andreas;Rueckert, Daniel;Ye, Jong Chul (ed.) Second International Workshop, MLMIR 2019. Shenzhen, China: Springer International Publishing (Second International Workshop, MLMIR 2019), pp. 205–214. Available at: https://doi.org/10.1007/978-3-030-33843-5.

Nicolas GP et al. (2018) ‘New Developments in Peptide Receptor Radionuclide Therapy.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine [Preprint]. Available at: https://doi.org/10.2967/jnumed.118.213496.

Antwi K et al. (2018) ‘Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.’, European journal of nuclear medicine and molecular imaging, 45(13), pp. 2318–2327. Available at: https://doi.org/10.1007/s00259-018-4101-5.

Valente LG et al. (2018) ‘Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study).’, Swiss medical weekly, 148, p. w14682. Available at: https://doi.org/10.4414/smw.2018.14682.

Omlin, Aurelius et al. (2018) ‘[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].’, Praxis, 107(19), pp. 1043–1051. Available at: https://doi.org/10.1024/1661-8157/a003054.

Berger CT et al. (2018) ‘The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis.’, Swiss medical weekly, 148, p. w14661. Available at: https://doi.org/10.4414/smw.2018.14661.

Nicolas GP et al. (2018) ‘Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(6), pp. 909–914. Available at: https://doi.org/10.2967/jnumed.117.199737.

Nicolas GP et al. (2018) ‘Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(6), pp. 915–921. Available at: https://doi.org/10.2967/jnumed.117.199760.

Nock B.A. et al. (2018) ‘New Gastrin Releasing Peptide Receptor-Directed [ 99m Tc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation’, Journal of Medicinal Chemistry, 61(7), pp. 3138–3150. Available at: https://doi.org/10.1021/acs.jmedchem.8b00177.

Rottenburger C et al. (2018) ‘A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation.’, Clinical nuclear medicine, 43(4), pp. 252–255. Available at: https://doi.org/10.1097/rlu.0000000000002005.